EMA (EU)
GUIDANCE FINAL
Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking
Published: 5/29/2026Detected: 5/29/2026
Summary preview
Updates the EMA CHMP guideline approach for nicotine dependency studies by proposing to widen scope beyond tobacco smoking to include dependence on smoke-free nicotine products (e.g., nicotine inhalation like…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpsychiatry
respiratory
clinical
safety
labeling
quality
manufacturing
#smoking cessation
#nicotine dependence
#confirmatory trials
#study design
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026